Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
escitalopram + quetiapine
- Development stage
- Phase 4
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of escitalopram, a selective serotonin reuptake inhibitor (SSRI), and quetiapine, an atypical antipsychotic. This combination is primarily used in the treatment of depressive episodes in bipolar disorder. Clinical studies have shown that the combination can be more effective than quetiapine alone in improving depressive symptoms, inhibiting inflammatory responses, and regulating oxidative stress without increasing the risk of mania.
02
Targets
DRD2 (Dopamine D2 Receptor)HRH1 (Histamine H1 Receptor)HTR2A (5-hydroxytryptamine receptor 2A)HTR2C (5-hydroxytryptamine 2C receptor)SERT (Sodium-dependent serotonin transporter)5-HT (Serotonin receptors)
Beyond the preview
Go deeper on escitalopram + quetiapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on escitalopram + quetiapine.